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ABSTRACT OF THESIS 
 
 
The Stimulation of Dendritic Cells by Cationic Lipids 
 
The discovery that cationic lipids can independently stimulate the immune system has 
generated interest in their potential as vaccine adjuvants. Here, we show that the cationic 
lipid R-DOTAP can independently stimulate type 1 interferon production in dendritic 
cells in both primary culture and immortalized cell culture. Levels of type 1 interferon 
production are cell line-dependent and limited in vitro by lipid-induced cell death. We 
show that cationic lipids can independently activate TLR-7 and TLR-9, suggesting a 
mechanism for type 1 interferon induction. This TLR-stimulatory activity is not restricted 
to R-DOTAP and can be extended to other similar cationic lipids in a lipid-specific and 
TLR-specific manner. 
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CHAPTER 1.  INTRODUCTION 
 
As the field of cancer immunotherapy has grown ever more sophisticated, with 
recent advances in CAR cell engineering1,2 and immune checkpoint inhibition3 showing 
great promise in the clinic, approaches to improve the oldest form of cancer 
immunotherapy – vaccination – continue to evolve4. The first rigorous attempts to 
artificially induce the immune system to fight cancers date back to the 1890s, when a 
doctor named William Coley inoculated sarcoma-afflicted patients with streptococcus 
cultures, based on earlier reports of spontaneous tumor regression in patients who 
contracted bacterial infections5,6. While he observed tumor regression in his patients, the 
immunological knowledge of the time was not sufficient to explain his results; this was 
almost two decades prior to Paul Erlich’s hypothesis the role of immune involvement in 
cancer progression7, and in fact Coley believed that the root cause of cancer could be 
traced to microorganisms.6   
With the passage of time came more nuanced and complete understandings of the 
immune system in ways relevant to immunotherapy. Dendritic cells were famously 
defined by Steinman and Cohn in 19738,9, followed quickly by proof of MHC restriction 
in 197410, although an understanding of peptide binding and structure with relation to 
MHC would not arise until over a decade later11. The existence and mechanisms of CD8+ 
T cells were elucidated throughout the 1970s through the 1990s, including the function of 
the thymus in T cell development, the structure of the TCR, and the formation and 
description of the concepts of T cell activation, tolerance and memory12. 
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The basic mechanism of action of vaccines is now fairly well understood22-26. 
Briefly, a vaccine-delivered antigen is taken up by antigen-presenting cells (APCs) such 
as dendritic cells. Upon activation by pathogen or damage-associated molecular patterns 
(PAMPS or DAMPS) along with stimulatory cytokines, dendritic cells will activate, 
mature, and migrate to the draining lymph nodes. Antigen is processed and presented 
through the exogenous pathway, which presents extracellular antigen to CD4+ helper T 
cells in the context of MHC Class I molecules, through the endogenous pathway, which 
presents intracellularly-derived antigen to CD8+ cytotoxic T lymphocytes (CTL) in the 
context of MHC Class II molecules, or, through the process of cross-presentation, 
processed through poorly defined pathways such that exogenous antigen is presented 
through MHC Class I to CD8+ CTLs. This final pathway is what allows a robust CD8+ T 
cell response against tumors, although the activation of both CD8+ and CD4+ 
lymphocytes are required to form an efficient, long-lasting immune response against 
tumors.  
From the perspective of modern anti-cancer vaccination, enormous strides were 
made with the identification of tumor-associated and tumor-specific antigens, beginning 
in the early 1990s and continuing to the present day. Early attempts at tumor vaccines 
used autologous and allogenic tumor cells, typically by injection of whole, irradiated 
tumor cell lysates, but these approaches have largely been left behind in favor of 
incorporating specific peptides in the vaccine21. The first tumor-associated gene to be 
identified was MAGE-1, discovered in 1991 by Pierre van der Bruggen13, followed by a 
number of others, including MART-114, gp10015, NY-ESO-116, and hTERT17. The 
broadly recognized difficulty with these early antigens arose from the fact that none of 
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these genes are specific to the tumor itself. Instead, it is the upregulation of these proteins 
in cancer cells that allows the breaking of self-tolerance and the establishment of an anti-
tumor response, but this also makes obtaining high response rates difficult20.  In spite of 
the associated difficulties, the FDA has approved two vaccines for use in the treatment of 
cancer. The BCG vaccine, approved for the treatment of urothelial carcinoma, can be 
viewed as a modern extension of the work done by Coley over a century earlier18. It is 
based on the injection of a live, attenuated strain of Mycobacterium bovis. Sipuleucel-T 
(Provenge) has been approved for metastatic castration resistant prostate cancer. As an 
autologous dendritic cell vaccine that contains on a prostate acid phosphatase-GMCSF 
fusion protein, Sipuleucel-T is the only approved anti-cancer vaccine that is dependent 
upon a TAA, and the 4.1-month improved survival time associated with the vaccine 
unfortunately represents some of the most effective, consistent results that antigen-
specific cancer vaccines have been able to provide19, 20. 
In light of the limited efficacy of therapeutic cancer vaccines as single agents, the 
rarity of the dendritic cell subset responsible for CD8+ T cell priming27, and the necessity 
of activating both CD4+ and CD8+ T cells to obtain a robust immune response, much 
recent work has focused on increasing the efficiency of antigen presentation and 
delivery.29-32 Cationic lipids were proposed as a vehicle for DNA transfection in 
eukaryotic cells in the late 1980s28, and they have since been expanded as delivery 
systems for protein34 and DNA vaccines33. Mechanistically, it is understood that the lipid 
nanoparticle will interact with the cell membrane via electrostatic forces and enter the 
target cell by an endocytotic, clathrin-dependent process.35, 36 The lipids fuse with 
endosomal compartments, where the cationic lipids in the delivery system will both 
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prevent the degradation of antigen by alkalizing the endosomal pH and destabilize the 
existing anionic endosomal membrane, resulting in the release of preserved endosomal 
proteins into the cytoplasm.37, 38 Cytoplasmic peptides are degraded by the proteasome 
and processed primarily through the cytosolic pathway to MHC class 1 molecules, which 
are presented on the surface of the cell. 39, 45 MHC class 1 presentation is responsible for 
stimulating a CD8+ cytotoxic T lymphocyte response.45  
More recently, it has been realized that cationic lipids can induce immune responses 
in an independent and varied fashion. Cationic lipids present in a variety of structures, 
and it appears that their ability to function as immune stimulators is dependent on 
structural factors that include the components of the polar head group and length of the 
carbon chains.40 A number of cationic lipids in the TAP and EPC families have been 
shown to induce CD80/86 expression, often used as a marker of maturation in dendritic 
cells, along with a number of inflammatory cytokines in, but only if the lipids were 
cationic as opposed to neutral or anionic.39-41 It has been proposed that cationic lipids act 
by mimicking the action of exogenous cationic signaling molecules such as arginine and 
spermine, as well as by modifying the activities of membrane-bound proteins by the 
disruption of the cell membrane.43 The cationic lipid diC14-amidine, in addition to the 
upregulation of CD80/86, induces secretion of IL-12, IL-6, TNF-α, and IFN-β  in both 
human and murine dendritic cell models.42 Similarly, RPR206252 induces TNF-α, IFN-γ, 
IL-6 and IL-1β  production in human and murine macrophage cell lines, although through 
a different mechanism44. 1,2-dioleoyl-3-trimethyl-ammonium-propane (DOTAP) has 
been shown to induce the upregulation of CD80/86 via an NF-κB-independent pathway, 
and to induce the production of a number of cytokines responsible for the activation, 
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recruitment, and expansion of dendritic cells and CD8+ cytotoxic T lymphocytes in an 
ERK and PI-3 kinase dependent fashion.40,41 Interestingly, this includes the 
downregulation of IL-1β , suggesting a cell-type or lipid-specific immunomodulatory 
effect. Subsequent work showed that this ERK/PI-3 kinase activation, as well as the 
upregulation of CD80/86 expression, was dependent on the DOTAP-induced production 
of reactive oxygen species.46 Interestingly, the ability of DOTAP to trigger immune 
responses may be highly conserved – recent work illustrates that DOTAP activates 
immune responses including ROS production and cell death in plant leaves.71 The action 
of DOTAP is enantiospecific; tumor regression assays with R-DOTAP/E7 peptide and S-
DOTAP/E7 peptide vaccines have demonstrated that CD8+ lymphocyte activation and 
tumor regression are found in mice treated with the R-DOTAP-based vaccine, whereas 
the S-DOTAP-based vaccine only caused a delay in tumor progression and a lack of 
CD8+ lymphocyte activation.47 
The diversity of mechanisms of action and downstream outcomes of different 
cationic lipids suggest that lipid selection in the context of vaccination could be used as a 
tool to stimulate specific and desirable signaling outcomes and has generated interest 
with an eye towards rational adjuvant design. Recently, the Woodward lab has described 
the action of an R-DOTAP-based vaccine containing either MUC-1 peptides or, for use in 
an HPV tumor system, E7 peptides57. The R-DOTAP-MUC1 formulation induced a more 
robust and polyfunctional T cell response when compared to a Montanide-based control 
and a control containing Freund’s adjuvant, IL-12, GM-CSF and an HBC helper epitope, 
as measured by IFN-γ, TNF-α, and IL-2 production. In an in vivo, murine, TC1 tumor 
model, an R-DOTAP based vaccine resulted in infiltration of antigen-specific CD8+ T 
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cells in the tumor and induced tumor regression, including regression of large tumors.  To 
investigate the increase of polyfunctional CD8+ T cells as a result of RDOTAP 
administration, we demonstrated the ability of RDOTAP to stimulate cross-presentation 
in an in vivo model using an adoptive transfer method with CFSE-labeled T cells specific 
to CD8+ and CD4+ epitopes of OVA such that proliferation of either labeled cell 
population would require cross-presentation of OVA-derived peptides. Not only did we 
observe significant levels of cross-presentation, but also noted enlargement of draining 
lymph nodes. In light of the previously reported immunostimulatory properties of 
DOTAP and other cationic lipids,39-44, 46, 47 we injected C57BL6/J mice with R-DOTAP 
and measured inflammatory gene expression in CD11c+ dendritic cells using Nanostring 
multiplex analysis. While we observed no increase of NF-κB-dependent cytokines, which 
is consistent with earlier reports of DOTAP activity30, there was a marked increase in the 
upregulation of IFN-α and IFN-β, as well as Stat 1 and CXCL10, both of which are 
produced in response to interferon production48,49,57. 
The possibility of a targeted induction of type 1 interferons (IFN) by R-DOTAP was 
intriguing. Type 1 IFN stimulate the cross-priming of CD8+ T cells in viral contexts54. In 
tumor models, Type 1 IFN signaling from the host is required to generate a pool of 
CD8α+ dendritic cells in draining lymph nodes responsible for CD8+ T cell cross-
priming55. Type 1 IFN production has also been shown to result in the retention of 
lymphocytes in lymph nodes through a CD69-dependent mechanism downstream of type 
1 IFN signaling.56 Taken together, this suggests a mechanism for both the enlargement of 
draining lymph nodes and the polyfunctionality of the T cell repertoire in response to 
vaccination. 
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Considering the potential importance of IFN and IFN-related genes in cationic lipid 
vaccines, we sought to develop an assay suitable for the detection of type 1 IFN in 
response to cationic lipid stimulation and to elucidate the mechanism of action 
responsible for that induction. Type 1 IFN can be observed through a reporter cell-based 
bioassay, expressed in a dose and cell type-dependent manner by BMDCs and 
immortalized cell lines after R-DOTAP exposure. This exposure is both related to and 
limited by cytotoxic effects in vitro. R-DOTAP induces type 1 IFN through the activation 
of the TLR-7 and TLR-9 pathways, in a mechanism that can be extended to other lipids 
in a structure-specific fashion.
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Cell Lines 
 
B16-Blue™ IFN-α/β cells (Invivogen, USA) and RAW 264.7 cells (ATCC) were 
cultured in RPMI medium with 10% FBS, 1mM sodium pyruvate, 1mM L-glutamine, 1x 
MEM non-essential amino acids, 100 U/ml of both penicillin and streptomycin, 100 
μg/mL Zeocin, and 50 μM β-mercaptoethanol (cRPMI).  
JAWS II (ATCC® CRL-11904™, USA), were cultured and maintained in 
Dulbecco’s modified eagle medium supplemented with 1mM sodium pyruvate, 1mM L-
glutamine, 100 U/mL of both penicillin and streptomycin, and 10 ng/mL recombinant 
mouse GM-CSF (Biolegend, USA).  
HEK-BlueTM Null, HEK-BlueTM human TLR-9, and HEK-BlueTM human TLR-7 
(Invivogen, USA) were cultured in Dulbecco’s modified eagle medium supplemented 
with 10% FBS, 100 μg/mL blastocidin, 100 μg/mL Zeocin, 100 U/mL penicillin and 
streptomycin, and 50 μM β-mercaptoethanol. 
 
2.2 Generation of murine bone marrow-derived dendritic cells 
 
C57BL6/J mice or B6.129S2-Ifnar1tm1Agt/Mmjax (IFNAR-/-) mice (Jackson 
Laboratories, USA) were euthanized by CO2 inhalation and cervical dislocation. Tibias 
and femurs were removed from the animals after sterilization with 70% ethanol and bone 
marrow flushed into cRPMI. The resulting mixture was passed three times through an 18-
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gauge needle to ensure generation of a single-cell suspension and then passed through a 
100 μm cell strainer. Cells were counted with a hemocytometer and plated in cRPMI 
medium supplemented with 5 μg/mL IL-4 and 20 μg/mL recombinant mouse GM-CSF 
(Biolegend, USA) at a concentration of 2x106 cells per plate. The medium was 
supplemented on days 3, 5, and 7 after initial plating, and cells were harvested on day 8 
for use in experiments. 
 
2.3 Type 1 interferon detection in murine bone marrow-derived dendritic cells 
 
Murine bone-marrow derived dendritic cells (mBMDC) were harvested 8 days after 
incubation by scraping and seeded in a 96-well plate at a concentration of 200,000 cells 
per well. RDOTAP dilutions in 280 mM sucrose and LPS dilutions in cRPMI were added 
at 2x the final concentration, and the plate was allowed to incubate for 18 hours at 37oC, 
5% CO2. After 18 hours, B16 Blue cells harvested with 0.05% Trypsin-EDTA were 
added to a second 96 well plate at 200,000 cells per well, followed by an equivalent 
volume of supernatant from the RDOTAP-exposed mBMDCs. A standard curve was 
generated with recombinant IFN-β in the same plate. The plate was allowed to incubate 
for 20-24 hours at 37oC, 5% CO2. 50 μL of this supernatant was then added to 150 μL 
Quanti-BlueTM detection reagent (InvivoGen, USA), and readings obtained with a 
spectrophotometer at 650 nm after 3 hours incubation. Analysis was performed using 
SoftMax Pro 5.3. Statistical significance was calculated with Student’s T tests, with p-
values of less than 0.01 being considered significant. 
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2.4 Type 1 interferon detection in cell cultures 
 
RAW 264.7 cells were harvested with 0.25% Trypsin. Type 1 IFN release was 
detected using the same protocol as above (“Type 1 interferon detection in mBMDCs”). 
Type 1 IFN release by JAWS II cells was detected in a similar manner, with the 
exception that RDOTAP was added at 5x final concentration rather than 2x. 
HEK-Blue NullTM, HEK-Blue hTLR-7TM, and HEK-Blue hTLR-9TM cells were harvested 
by tapping the bottom of the cell flasks, seeded in a 96-well plate at 100,000 cells per 
well, and incubated at 37oC, 5% CO2 overnight. Media was removed from the well, and 
5x concentration lipid dilutions were allowed to sit directly on the cells for 5 minutes 
before being diluted with cDMEM and incubated for 20 hours. 50 μL supernatant was 
removed from each well and incubated with 150 μL Quanti-BlueTM detection medium, 
with readings taken with a SpectramaxTM M5 spectrophotometer at 3 hours. Analysis was 
performed using SoftMax Pro 5.3 and statistical significance calculated using Student’s T 
tests. P-values of less than 0.01 were considered significant. 
 
2.5 Cytotoxicity Assays 
 
JAWS II cells were harvested with 0.25% trypsin and washed with HBSS. 1x106 
cells were suspended in 250 μL cRPMI and allowed to incubate with 1 μL NK-TVATM 
dye (Cellular Technology Limited, USA) for 30 minutes at 37oC, 5% CO2. The 
suspension was washed with DMEM media, spun down at 300xG, and the pellet 
resuspended in 2 mL DMEM. 10 μL of this suspension + 50 μL cDMEM were added to 
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each well, for a final count of 5,000 cells per well. Starting readings were obtained using 
a CTL Immunospot analyzer (Cellular Technology Limited, USA). 50 μL of RDOTAP 
was added, in triplicate, at 2x final concentration per well, and images obtained at 10 
minutes and 2.5 hours. 
Lactate dehydrogenase assays were performed using the Cytotoxicity Detection KitPLUS 
(LDH) (Roche, Germany). Values were obtained by sampling 25 μL supernatant from the 
relevant lipid-treated cell type after the full period of incubation, diluting it in 25 μL 
Dulbecco’s PBS, and incubating it at 37oC, 5% CO2 for 15 minutes, stopping the reaction 
with 50 μL of the provided stop solution, and taking readings at 450 nm on a 
spectrophotometer. 
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CHAPTER 3. RESULTS 
3.1 R-DOTAP stimulation induces a type 1 interferon response in murine bone 
marrow-derived dendritic cells 
 
It has been established that cationic lipids are capable of generating specific 
immune responses.30,42,44 In support of this, recent experiments from our lab have 
demonstrated that IFN-α, IFN-β, and the interferon-related genes CXCL10 and Stat1 are 
upregulated in mice after injection with R-DOTAP nanoparticles, and that an R-DOTAP-
based vaccine induced strong cross-presentation, cross-reactive CD8+ T cell repertoires, 
and enlargement of draining lymph nodes in immunized mice.56 To interrogate the role 
and mechanism of R-DOTAP in generating type 1 IFNs, we generated bone marrow-
derived dendritic cells from C57BL6/J mice and exposed them to varying concentrations 
of R-DOTAP in vitro. We observed a strong dose-dependent response, peaking at 150 
μM and dropping off at higher dosages (Figure 3.1A). Previously, we showed that the 
size of draining lymph nodes and the upregulation of CD69 in mice injected with R-
DOTAP was attenuated in IFNαR knockout mice. Therefore, we also generated murine 
BMDC cultures from an IFNαR knockout strain. IFN production was still observed, 
again peaking at 150 μM, but was attenuated when compared to wild type C57BL6/J 
BMDC cultures (Figure 3.1B). Given the demonstrated role of the IFNαR receptor in the 
production of type 1 IFNs through a positive feedback mechanism and our observations 
that IFNαR knockout mice did not exhibit the same CD69 upregulation and size increase 
of the draining lymph nodes in response to R-DOTAP injection, we hypothesize that the 
IFNα receptor is important in amplifying the production if IFNα in these cultures. 
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3.2 R-DOTAP stimulates type 1 interferon production in immortalized cell cultures 
 
Although type 1 IFN expression in BMDCs was demonstrable over multiple 
experiments, it was desirable to develop an immortalize cell culture model to probe the 
mechanism of R-DOTAP stimulated interferon expression without the individual 
variation inherent in murine models, and to allow experiments to be performed at a more 
rapid rate with fewer animal deaths. There have been a number of cell culture lines used 
to demonstrate specific immune responses to cationic lipids, including RAW-BlueTM, 
DC2.4, TC-1, and transfected human embryogenic kidney (HEK) cells.41,42,44,46 The 
RAW264.7 cell line has been previously used to evaluate the immune responses of 
cationic lipids and lipoplexes.60,61 Following this precedent, we exposed RAW264.7 
macrophage with R-DOTAP nanoparticles for a period of 18 hours and looked for  R-
DOTAP stimulation using a B16-BlueTM bioassay in a manner similar to the assay used 
successfully with BMDCs (Figure 3.2A). An observable amount of type 1 IFN was 
produced, peaking at approximately 150 μM and dropping off at higher dosages, but the 
levels of interferon produced were low, comparable to those produced by the IFNαR 
knockout BMDCs. Because a cell line that produced large amounts of type 1 IFN was 
preferred for the purpose of mechanistic studies, we instead examined the JAWS II 
murine dendritic cell line using a similar method. We saw a dose-dependent production 
of type 1 IFN in response to R-DOTAP stimulation, in excess of the amount produced by 
BMDCs in response to cationic lipid stimulation (Figure 3.2B). Interestingly, JAWS II 
appeared to require higher levels of DOTAP compared to BMDC, with the response 
peaking around 450 μM. 
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3.3  R-DOTAP-induced type 1 interferon production is correlated to and limited by 
cytotoxicity in vitro 
 
In cell culture models, the R-DOTAP-induced type 1 IFN dose-response curve 
exhibited a peak response that subsequently decreased at higher doses. We also observed 
the formation of precipitates and altered cell morphology in wells containing higher doses 
of R-DOTAP when left overnight. Upon observation under a light microscope, the cell 
population of these wells appeared to be lysed, with few intact cells and large amounts of 
cell debris observed at high R-DOTAP concentrations (data not shown). In conjunction 
with the reported toxicity of cationic lipids62,63, this led us to suspect that the decrease in 
type 1 IFN production might be attributable to the death of cells in culture rather than 
some form of high-dose inhibition. To examine this, we treated JAWS II cells with NK-
TVATM dye, a visual assay in which cells are labeled with a fluorescent dye that is lost 
upon cell lysis. Dyed cells were treated with different concentrations of R-DOTAP and 
imaged after 10 minutes and 2.5 hours. Visible cells were counted at each time point and 
compared to images of the wells prior to R-DOTAP exposure. Population survival was 
expressed as a percentage of the original population. We observed rapid, concentration-
dependent cytotoxicity, with higher doses of R-DOTAP killing over 95% of the cell 
population within a 2.5-hour time frame (Figure 3.3A). Because the mechanism of 
cationic lipid fusion with target cells is believed to involve destabilization of the plasma 
membrane37, we were concerned that the visual assay might be unreliable; the 
destabilization could allow release of the fluorescent dye from the target cells, resulting 
in an artificially high measure of cytotoxicity. To provide a separate measure of 
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cytotoxicity, we measured cytotoxicity using a lactate dehydrogenase (LDH) assay. 
While overall cytotoxicity was less than observed with the NK-TVATM assay, indicating 
a degree of fluorescent labeling loss due to membrane perturbation, high levels of 
cytotoxicity were still observed (Figure 3.3C). When combined, the two assays suggest 
that cell death in response to R-DOTAP exposure occurs rapidly and levels off, with the 
surviving cells producing the type 1 IFN detected by the bioassay. The loss of type 1 IFN 
production at higher dosage levels is therefore not necessarily due to a lower level of 
interferon production per cell, but because fewer cells remain alive to produce it.  
 
3.4 Cationic lipids activate TLR-7 and TLR-9 
 
Type 1 interferons can be produced through the actions of the TLR-9 subfamily of 
toll-like receptors. It has been demonstrated that cationic lipids will fuse with the 
endosomes of target cells and destabilize them,37,38 so we reasoned that R-DOTAP might 
interact with TLR-9 family receptors to stimulate type 1 IFN production. Because HEK 
cells modified to overexpress TLRs have been successfully used to demonstrate the 
dependence of cationic lipid signaling on TLRs44, we obtained HEK-BlueTM cells 
modified to express individual TLRs, either TLR-7 or TLR-9, along with a secreted 
alkaline phosphatase (SEAP) reporter gene controlled by an NF-κB promotor. HEK-
BlueTM Null1 cells were used as a negative control. We observed both TLR-7 and TLR-
9-dependent SEAP expression in response to R-DOTAP stimulation (Figure 3.4A)57. 
Cationic lipid-induced immune responses have been shown to be dependent on the nature 
of the lipid head group and carbon tails.40 To determine if the responses observed in R-
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DOTAP-stimulated cells held for other cationic lipids, we stimulated HEK-BlueTM TLR-
9, TLR-7, and Null1 cells with the cationic lipid 1,2-di-O-octadecenyl-3-
trimethylammonium propane (DOTMA), the cationic lipid 1,2-dioleoyl-sn-glycero-3-
ethylphosphocholine (chloride salt) (DOEPC), and the neutral lipid 1,2-Dioleoyl-sn-
glycero-3-phosphocholine (DOPC). Consistent with previous reporting with other 
downstream targets, the neutral lipid (DOPC) was unable to induce a response in either 
the TLR-9 or TLR-7 expressing cell line (Figure 3.4D). The cationic lipids induced 
responses; DOEPC produced both TLR-7 and TLR-9 dependent SEAP expression in a 
dose-dependent manner (Figure 3.4B), while DOTMA more specifically produced TLR-9 
dependent responses when compared to the null control line (Figure 3.4C). 
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A.      B. 
     
Figure 3.1   Type 1 interferon expression is induced by RDOTAP in BMDCs in a dose-
dependent, IFNαR-dependent manner. Murine bone marrow-derived dendritic cells 
from C57BL6/J (Figure 3.1A) or an IFNαR (-/-) strain (Figure 3.1B) were exposed to 
varying concentrations of R-DOTAP for a period of 18 hours, and type 1 IFN production 
quantified with a B16-BlueTM reporter cell-based bioassay. Responses in both cell lines 
peaked at approximately 150 μM, but the response magnitude in IFNαR(-/-) derived cells 
was attenuated when compared to the wild type. Asterisks indicate statistical significance 
(p<0.01). 
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A.     B. 
 
Figure 3.2  R-DOTAP responses in vitro are cell-type dependent. RAW264.7 
macrophages (Figure 3.2A) and JAWS II dendritic cells (Figure 3.2B) were exposed to R-
DOTAP for a period of 18 hours, and type 1 IFN production quantified with a B16-BlueTM 
reporter cell-based bioassay. Expression of type 1 IFN was highly dependent on cell type, 
with RAW264.7 expression comparable to IFNαR(-/-) BMDC expression, and JAWS II 
expression higher than WT C57BL6/J-derived BMDC expression. Asterisks represent 
statistical significance (p<0.01). 
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A. 
 
B.      C. 
 
Figure 3.3  Type 1 IFN expression is related to and limited by the cytotoxic effects of 
R-DOTAP exposure. JAWS II cells were stained with CTL dye and exposed to R-
DOTAP. Cells were imaged at 10 minutes and 2.5 hours, and cell death quantified as a 
percent of initial cell density (Figure 3.3A). JAWS II cells were exposed to R-DOTAP for 
a period of 18 hours, and supernatant examined using an LDH release assay to quantify 
cell death (Figure 3.3C). IFN production was quantified from the same plate using a B16-
BlueTM reporter cell-based bioassay. JAWS II IFN production is the same experiment as in 
Figure 3.2B, provided here for ease of reference.   
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A. 
  
B. 
  
C.  
  
D. 
  
Figure 3.4  Cationic lipids stimulate TLR-9 and TLR-7 in a lipid-specific manner. 
HEK-BlueTM hTLR9, hTLR7, and Null cell lines were incubated with cationic and neutral 
lipids for 20 hours and SEAP release quantified by spectrophotometric readings in the 
presence of a reporter dye. DOPC, a neutral lipid, did not induce either TLR-9 or TLR-7 
activity (Figure 3.4D), while the cationic lipids DOEPC and R-DOTAP induced both 
(Figure 3.4A and B). DOTMA, another cationic lipid, induced TLR-9 activity but not TLR-
7 activity (Figure 3.4C). Asterisks represent statistical significance (p<0.01). 
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CHAPTER 4. DISCUSSION 
 
Cationic lipids have been well-established as agents that increase the efficiency of 
antigen and nucleic acid delivery to target cells.28,33,34 Previous work indicates that the 
actions of cationic lipids are linked to structure, specifically the nature of the cationic 
head group and the carbon chains, but the exact nature of the mechanisms by which they 
induce responses has yet to be well described.40,43 The Huang lab has shown that DOTAP 
upregulates CD80/86 expression on exposed dendritic cells and that it activates PI-3 
kinase and ERK, leading to the production of CCL2, CCL3, and CCL4 and the 
downregulation of IL-1β .40,41 Further work from the same laboratory indicates that ERK 
activation is dependent on the production of reactive oxygen species produced in the first 
10 minutes of stimulation by DOTAP, providing both a mechanism for cationic lipid-
induced chemokine generation, co-stimulatory molecule expression, and apoptosis.46 We 
demonstrate that R-DOTAP induces the production of type 1 IFN in both BMDCs and 
immortalized cell lines in an IFNαR-dependent and cell-type dependent manner. The 
peak of the response, at 150 μM, corresponds nicely to previous work that puts peak 
CD80/86 expression in BMDC cultures in response to R-DOTAP stimulation at the same 
concentration, although given the in vitro cytotoxicity levels demonstrated here and 
elsewhere46 this is likely to be an artifact of the assay limitations rather than a reflection 
of an ideal dose in a live system. Type 1 IFN production suggests an explanation for a 
number of previous observations about the effects of DOTAP, including the upregulation 
of CD80/86 expression, the activation of PI-3 kinase, and the expression of the IFN-
dependent cytokine CCL2.67-70 The extent to which IFN activity is connected to ROS-
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induced ERK activation remains to be elucidated. The stimulation of type 1 IFN 
production in immortalized cell cultures provides an avenue to explore the mechanism of 
action of cationic lipid stimulation without the individual variation present in BMDC 
cultures. We observed an increased ability to produce type 1 interferon in the JAWS II 
murine dendritic cell line when compared to BMDCs, while experiments with 
RAW264.7 macrophages failed to produce IFN at comparable levels to either JAWS II or 
BMDC cultures. RAW264.7 macrophages have been previously used to describe the 
stimulatory effects of cationic lipids.60 The cell line has previously been shown to 
produce IFN-β  mRNA in response to cationic lipid/DNA lipoplex stimulation, although 
only in a transient fashion early after stimulation61. This, coupled with our data, suggests 
that the immunomodulatory effects of cationic lipids are dependent on cell type, but that 
the effects can be studied in appropriate immortalized cell lines as well as in BMDC 
cultures. 
Using the JAWS II cell line, we investigated the cytotoxic effects of R-DOTAP 
exposure on cell culture. Cationic lipid-dependent cytotoxicity has been well 
reported,42,62,63 and we suspected that the reduced expression of type 1 interferon in vitro 
at high dosages of R-DOTAP was a result of this toxicity. We found a dose-dependent 
increase in cell death upon exposure to R-DOTAP that appears to limit the ability of cells 
to produce responses in vitro. This suggests limitations to the study of R-DOTAP 
stimulation using a cell model system, in that the magnitude of the responses elicited 
could conceivably be inhibited by the death of cells in culture in a manner not reflective 
of the in vivo reality. 
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To investigate the mechanism underlying the ability of R-DOTAP to induce type 1 
IFN expression, we examined the ability of the lipid to activate TLR-9 and TLR-7 in 
HEK cells modified to express either TLR-7 or TLR-9 in a specific fashion. The potential 
of cationic lipids to interact with toll-like receptors has precedent; the ability of the 
cationic lipid diC14-amidine to induce IFN-β  and TNF-α has been tied to stimulation of 
TLR-4.42 TLR recognition was specific; TLR-2 and TLR-3 were not shown to be 
involved in diC14-amidine immunostimulation, and the response in the presence of LPS 
was attenuated, suggesting a specific recognition of the unsaturated carbon chains of 
diC14-amidine by TLR-4.42 Conversely, RPR206252 acts through the PRRs TLR-2 and 
NLRP-3.44 Taken together, this suggests that different PRRs can recognize cationic lipids 
in a structure-specific manner to induce discrete downstream effects. In line with these 
reports, we observed the stimulation of SEAP production by TLR-7 and TLR-9 in 
response to R-DOTAP and sought to characterize the responses of structurally related 
lipids DOEPC and DOTMA. Both DOEPC and DOTMA, like DOTAP, contain 
quaternary amino head groups and carbon tails of similar length. The effects of the 
neutral lipid DOPC were examined as a control. DOEPC induced both TLR-7 and TLR-9 
mediated SEAP production, peaking around 150 μM in a manner similar to R-DOTAP, 
while DOPC induced neither a TLR-7 or TLR-9 mediated response. DOTMA induced 
TLR-9 mediated SEAP production, but did not induce more TLR-7 mediated production 
compared to a null control cell line. The reason for this specificity in the case of DOTMA 
is unclear. Differences in immune responses are typically attributed to the structure of the 
head group and carbon tails40, and the failure of the neutral lipid DOPC to activate either 
TLR-7 or TLR-9 in this study supports this. However, DOTMA, R-DOTAP, and DOEPC 
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all contain similar head groups and carbon tails. DOTMA possesses an ether linker region 
rather than an ester linker (found in DOEPC and R-DOTAP), and while there do not 
appear to be any reports that linker regions affect immunostimulatory ability, a structure-
dependent model of TLR stimulation allows the possibility of unreported structure-
dependent activity. 
Another possibility regarding the mechanism of TLR activation is related to the 
lipid-associated cytotoxic effects demonstrated here and elsewhere.46,62,63 Consistent with 
past observations of cationic lipid-dependent cytotoxicity,42 we observed rapid and 
extensive cell death as a result of R-DOTAP exposure using both visual fluorescence-
based assays and more traditional LDH release assays. It is difficult to separate the 
release of type 1 IFN from the presence of cell death – we did not observe type 1 IFN 
production at dosages too low to induce cell death, but whether this is because cell death 
is required to induce the production of type 1 IFNs or simply because dosage levels were 
too low to cause either cell death or TLR stimulation is unclear. However, TLR-7 and 
TLR-9 are both capable of responding to endogenous RNA and DNA, respectively, and it 
has been known for a number of years that TLR-9 and TLR-7 respond strongly to 
DOTAP/RNA or DNA lipoplexes74,75, which raises the possibility that cationic lipids are 
taking up nucleic acids released from lysed cells and transporting them into endosomes, 
where they can be recognized by TLR-7 or TLR-9.35-38  
The finding of lipid- induced IFN production has the potential for use in the clinic. 
IFN-α has both been investigated and approved by the FDA for the treatment of hairy cell 
leukemia50 and melanoma51, and it has been found effective in a number of other 
malignancies52. IFN therapy has, however, resulted in significant toxicities, including 
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hepatotoxicity, fatigue, fever, nausea, and depression.52,53 Because the mechanism of type 
1 IFN-mediated anti-tumor activity is predominately dependent on hematopoietic targets 
rather than the direct response of neoplastic cells,65 the ability to induce type 1 IFN 
expression in a targeted manner in physiologically relevant contexts presents an 
opportunity to avoid toxicities associated with systemic IFN administration.  
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